ArticleMolecular biomedicine2026
miR-486-5p suppresses autophagy in hepatocellular carcinoma via activation of the AKT/mTOR signalling pathway.
Article in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Autophagy is controlled by a complex signalling network and is closely linked to the initiation and progression of hepatocellular carcinoma (HCC). However, how microRNAs (miRNAs) regulate autophagy in HCC remains incompletely understood. In this study, we identified microRNA-486-5p (miR-486-5p) as a tumour-associated microRNA that is enriched in circulating exosomes derived from patients with HCC. Elevated miR-486-5p promoted proliferation and suppressed apoptosis in HCC cell lines under stress conditions. Mechanistically, miR-486-5p directly targets the 3' untranslated region of the phosphatase and tensin homologue (PTEN) gene, thereby decreasing the production of the PTEN protein and consequently leading to the activation of the protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signalling pathway. This phenomenon was accompanied by the inhibitory phosphorylation of unc-51 like autophagy-activating kinase 1 (ULK1), which resulted in impaired autophagy. The pharmacological inhibition of AKT or mTOR led to the restoration of autophagy and the attenuation of miR-486-5p-driven growth and survival advantages. Furthermore, the transcription factor MYB was found to bind the promoter of ankyrin-1 (ANK1), the host gene of miR-486-5p, and to drive its expression. In an orthotopic liver tumour model, the liver-targeted delivery of miR-486-5p accelerated tumour expansion, an effect that was reversed by AKT or mTOR blockade. Collectively, these findings delineate a MYB/miR-486-5p/PTEN/AKT/mTOR signalling axis that constrains autophagy to facilitate HCC progression, suggesting potential avenues for biomarker development and therapeutic intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.